Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Axa S.A.

Axa S.A. increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 341,734 shares of the company’s stock after purchasing an additional 8,035 shares during the period. Axa S.A. owned 0.34% of Neurocrine Biosciences worth $42,953,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of NBIX. Dodge & Cox raised its position in shares of Neurocrine Biosciences by 83.5% during the 1st quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock valued at $612,129,000 after buying an additional 2,518,199 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Neurocrine Biosciences by 59.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock worth $535,659,000 after purchasing an additional 1,590,749 shares during the period. Norges Bank acquired a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth about $122,278,000. Los Angeles Capital Management LLC raised its holdings in Neurocrine Biosciences by 19,454.9% in the 2nd quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock valued at $93,595,000 after buying an additional 740,842 shares during the period. Finally, Wellington Management Group LLP lifted its position in Neurocrine Biosciences by 44.0% in the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock valued at $232,037,000 after buying an additional 640,556 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Kyle Gano sold 300 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total transaction of $42,591.00. Following the transaction, the chief executive officer owned 140,407 shares of the company’s stock, valued at $19,933,581.79. This trade represents a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director William H. Rastetter sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total value of $2,732,760.00. Following the completion of the transaction, the director directly owned 40,360 shares in the company, valued at approximately $6,127,455.20. The trade was a 30.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,300 shares of company stock worth $4,925,901 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $155.02 on Wednesday. The company has a market cap of $15.46 billion, a price-to-earnings ratio of 37.09, a price-to-earnings-growth ratio of 1.02 and a beta of 0.27. The stock’s 50-day moving average is $144.31 and its two-hundred day moving average is $136.65. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, beating the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The firm had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. During the same quarter in the prior year, the company posted $1.81 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 27.8% compared to the same quarter last year. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. UBS Group lifted their price target on shares of Neurocrine Biosciences from $188.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Piper Sandler boosted their target price on Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Morgan Stanley decreased their price target on Neurocrine Biosciences from $178.00 to $173.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus boosted their price objective on Neurocrine Biosciences from $174.00 to $183.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.00.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.